Endonovo Therapeutics Bundle
Who owns Endonovo Therapeutics?
Is Endonovo still controlled by founders, insiders, or recent institutional backers after repeated financings and restructurings? This piece traces ownership shifts, major holders, and governance influence shaping strategy and control.
Endonovo, founded 2008 and pivoted in 2016 to the SofPulse bioelectronic platform, raised capital via equity, convertible notes, and PIPEs, diluting founders and populating cap tables with insiders and retail investors. Current control reflects a mix of management stakes, convertible-note holders, and active retail trading on OTC, affecting board composition and strategy; see Endonovo Therapeutics Porter's Five Forces Analysis
Who Founded Endonovo Therapeutics?
Founders and early ownership of Endonovo Therapeutics centered on a small group of insiders led by Alan Collier, with founder equity, options and early angel rounds consolidating control around the SofPulse pulsed electromagnetic field strategy.
Founder leadership
Alan Collier served as early CEO/Chairman and held a controlling or near-controlling stake via common shares and options.
Scientific contributors
Key scientists contributed IP and know-how for the SofPulse PEMF device in exchange for equity and milestone payments.
Predecessor entity
The company began as Hanover Portfolio Acquisitions, Inc. (2008), where founder/promoter equity dominated early capitalization.
Early financing
Capital came from founders, friends-and-family rounds and a small circle of angels before structured financings post-2013.
Vesting and IP assignment
Typical agreements used 3–4 year vesting with 1-year cliffs and assignment of patents to the company for stock and milestones.
Founder protections
Early charters featured board nomination rights and supermajority consent on IP transfers to protect foundational ownership.
Early ownership was concentrated among insiders and angels, with buy-sell clauses to repurchase unvested shares and selective buyouts to streamline the cap table as SofPulse became the strategic focus.
Key ownership facts
Founders held dominant early positions; institutional investor presence was minimal before 2013, changing with later financings. For further market context see Competitors Landscape of Endonovo Therapeutics
- Founder and promoter equity initially comprised the majority of shares and voting power
- Alan Collier maintained a controlling or near-controlling stake via common stock plus options
- Early seed and friends-and-family rounds funded IP consolidation and regulatory steps
- Protective provisions and buy-sell mechanisms reduced cap table fragmentation as advisors rotated out
Endonovo Therapeutics SWOT Analysis
- Complete SWOT Breakdown
- Fully Customizable
- Editable in Excel & Word
- Professional Formatting
- Investor-Ready Format
How Has Endonovo Therapeutics’s Ownership Changed Over Time?
Key financing events from 2013–2025 — convertible-note rounds, PIPEs, registered offerings and vendor share issuances tied to product commercialization — materially expanded the float and dispersed ownership, shifting control from concentrated insiders toward a predominantly retail public float and episodic institutional/convertible holders.
| Period | Primary Ownership Drivers | Resulting Shareholder Profile |
|---|---|---|
| 2013–2017 | Private placements, convertible notes with variable conversion pricing, warrants tied to SofPulse commercialization | Rising outstanding shares; insider dilution; financing-driven float expansion |
| 2018–2021 | PIPEs, note exchanges with OID and resets, registered offerings | Lower insider %; larger OTC retail base; limited sustained institutional stakes |
| 2022–2024 | Equity-linked financings, vendor-share issuances to support sales/manufacturing | Beneficial ownership dispersed among small funds and HNW investors; no >10% steady institutional holder |
| 2024–2025 (current) | Milestone and commercial-validation focus, episodic convertible investors, retail selling into liquidity | Majority public float; insiders meaningful but non-controlling; 5–9.9% episodic holders |
The evolution reflects a trade-off: securing runway for trials, marketing and manufacturing while prioritizing near-term liquidity over concentrated control, leading to a governance profile typical of micro-cap medical-device issuers.
Ownership Evolution — Key Takeaways
Who owns Endonovo Therapeutics today is the result of successive dilutive financings and secondary trading that expanded the public float and reduced controlling insider stakes.
- Insiders/management hold meaningful but non-controlling common stock, options and RSUs
- Convertible/PIPE investors often appear as 5–9.9% holders around financings, then decline
- Retail investors on the OTC market comprise the majority of outstanding shares
- No consistent institutional investor exceeded 10% across consecutive filings (2022–2024)
For a focused review of strategic implications tied to ownership changes and commercial milestones, see Growth Strategy of Endonovo Therapeutics.
Endonovo Therapeutics PESTLE Analysis
- Covers All 6 PESTLE Categories
- No Research Needed – Save Hours of Work
- Built by Experts, Trusted by Consultants
- Instant Download, Ready to Use
- 100% Editable, Fully Customizable
Who Sits on Endonovo Therapeutics’s Board?
As of mid-2025 the board of Endonovo Therapeutics centers on a compact slate led by the CEO serving as chair alongside independent directors with medical device, regulatory, and capital markets experience; investor-appointed seats have typically appeared as observer roles tied to financings rather than permanent directorships.
| Director | Role / Background | Voting Status |
|---|---|---|
| CEO / Chair | Executive leadership; operational control and incumbency advantages | Voting director, common stock aligned |
| Independent Director A | Medical device / regulatory experience | Voting director, independent |
| Independent Director B | Capital markets / finance background | Voting director, independent |
Board seats tied to investors have more often been implemented via observer rights during financing rounds, reflecting transactional influence rather than persistent control; the company maintains a one-share–one-vote common stock structure with no publicized dual-class or super-voting shares through 2024–2025.
Board composition and voting dynamics
Voting power at Endonovo is dispersed, with no single beneficial owner consistently above 20%; governance frictions have centered on financing terms rather than proxy fights.
- Board driven by CEO incumbency and independent expertise
- Investor influence mainly via observer rights tied to financings
- One-share–one-vote common stock; no dual-class or golden share reported
- Diffuse shareholder base — no consistent > 20% holder as of 2024–2025
For contextual background on market positioning and investor mix see Target Market of Endonovo Therapeutics; filings through 2024–2025 (SEC Forms 3/4/13D/G and annual proxy statements) remain the authoritative sources for Endonovo Therapeutics ownership, Endonovo shareholders, and Endonovo beneficial owners details.
Endonovo Therapeutics Business Model Canvas
- Complete 9-Block Business Model Canvas
- Effortlessly Communicate Your Business Strategy
- Investor-Ready BMC Format
- 100% Editable and Customizable
- Clear and Structured Layout
What Recent Changes Have Shaped Endonovo Therapeutics’s Ownership Landscape?
Since 2021 Endonovo Therapeutics ownership has shifted toward a more distributed public float after recurring equity and convertible note financings to commercialize SofPulse, reducing insider percentage ownership despite option refreshes; PIPE participant secondary sales created transient 5–10% holders around conversion windows.
| Period | Financing Type | Ownership Impact |
|---|---|---|
| 2021–2022 | Equity raises & convertible notes | Increased public float; insiders diluted; convertibles introduced potential future dilution |
| 2023 | PIPE conversions & secondary sales | Transient 5–10% holders; more distributed cap table; retail participation rose |
| 2024–2025 | Targeted raises, distributor advances, licensing | Management emphasised non-dilutive channels; possibility of milestone-linked equity raises remains |
Industry trends show increased retail ownership and activist screening in small-cap medtech, but Endonovo has not faced major activist campaigns; payer-aligned focus on opioid-sparing post-op pain, wound care, and inflammation could draw strategic or distributor-linked investors if new clinical data validates reduced LOS and opioid use.
Recent financing uses
Proceeds from 2021–2025 financings were allocated to inventory, clinical marketing, and reimbursement initiatives to support SofPulse commercialization.
Cap table dynamics
Convertible note conversions and PIPE participant resale windows produced transient concentrated stakes and a broader retail base in the shareholder registry.
Potential ownership catalysts
510(k) expansions, hospital procurement deals, or out-licensing for ARDS/cytokine storm could attract strategic investors and reduce reliance on convertibles.
Management stance
2024–2025 communications emphasise partnerships and non-dilutive channels (distributor advances, asset licensing) while not ruling out equity raises tied to commercialization milestones.
For background on revenue outlook and commercial strategy that inform investor interest, see Revenue Streams & Business Model of Endonovo Therapeutics.
Endonovo Therapeutics Porter's Five Forces Analysis
- Covers All 5 Competitive Forces in Detail
- Structured for Consultants, Students, and Founders
- 100% Editable in Microsoft Word & Excel
- Instant Digital Download – Use Immediately
- Compatible with Mac & PC – Fully Unlocked
- What is Brief History of Endonovo Therapeutics Company?
- What is Competitive Landscape of Endonovo Therapeutics Company?
- What is Growth Strategy and Future Prospects of Endonovo Therapeutics Company?
- How Does Endonovo Therapeutics Company Work?
- What is Sales and Marketing Strategy of Endonovo Therapeutics Company?
- What are Mission Vision & Core Values of Endonovo Therapeutics Company?
- What is Customer Demographics and Target Market of Endonovo Therapeutics Company?
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.